Related Experiment Video
Updated: Jul 15, 2026

Detection of Toxin Translocation into the Host Cytosol by Surface Plasmon Resonance
Published on: January 3, 2012
Amiodarone and bepridil inhibit anthrax toxin entry into host cells
Ana M Sanchez1, Diane Thomas, Eugene J Gillespie
1Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Researchers screened small molecules to find new ways to combat anthrax lethal toxin. Two heart medications, amiodarone and bepridil, showed potent anti-lethal toxin effects by blocking toxin entry into cells.
Area of Science:
- Microbiology
- Pharmacology
- Toxicology
Background:
- Bacillus anthracis lethal toxin is a key factor in anthrax virulence.
- Developing countermeasures against anthrax lethal toxin is crucial for public health.
- Existing treatments may have limitations, necessitating novel therapeutic strategies.
Purpose of the Study:
- To identify novel small molecules with anti-anthrax lethal toxin activity.
- To characterize the antitoxic properties of identified compounds.
- To investigate the mechanism of action for potent antitoxic compounds.
Main Methods:
- Screening of approximately 500 small molecules using a cell-based assay.
- Assessing the ability of compounds to protect RAW 264.7 macrophages from lethal toxin-mediated killing.
- Characterizing the two most potent compounds, amiodarone and bepridil.
- In vitro and in vivo testing of antitoxic efficacy and mechanism.
Main Results:
- Nineteen compounds demonstrated protective effects against anthrax lethal toxin.
- Amiodarone and bepridil were identified as the most potent antitoxic compounds.
- These drugs, used for cardiac conditions, protected macrophages at relevant concentrations.
- Antitoxic activity is attributed to blocking endosomal acidification and toxin entry.
- Amiodarone significantly enhanced survival in a lethal toxin-challenged rat model.
Conclusions:
- Amiodarone and bepridil possess significant anti-anthrax lethal toxin properties.
- Blocking endosomal acidification is a viable strategy to inhibit anthrax toxin.
- Existing cardiovascular drugs may offer potential as novel anthrax antitoxins.
- Further investigation into amiodarone and bepridil as anthrax therapeutics is warranted.
Related Concept Videos
Inhalation Anthrax
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Diphtheria
Receptor-mediated Endocytosis
Clathrin-Mediated Endocytosis of LDL
One well-characterized example of receptor-mediated endocytosis is the...
Receptor-mediated Endocytosis
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

